{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:15:19Z","timestamp":1790651719296,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Postgraduate Innovation Research and Practice Program of Anhui Medical University","award":["YJS20230031"],"award-info":[{"award-number":["YJS20230031"]}]},{"name":"Natural Science Foundation of Anhui Province Higher Education Institution, Key Project","award":["2022AH050760"],"award-info":[{"award-number":["2022AH050760"]}]},{"name":"Anhui Province Major Science and Technology Special Program Fund","award":["201903a07020030"],"award-info":[{"award-number":["201903a07020030"]}]},{"name":"Project funded by Anhui Medical University Scientific Research Fund","award":["2022XKJ212"],"award-info":[{"award-number":["2022XKJ212"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Serine\/arginine repetitive matrix 2 (SRRM2) has been implicated in tumorigenesis, cancer development, and drug resistance through aberrant splicing; however, its correlation with multiple myeloma (MM) has not been reported. We investigated the potential of SRRM2 as a biomarker and immunotherapeutic target in MM by examining its expression in MM cells using flow cytometry. Our study included 95 patients with plasma cell disease, including 80 MM cases, and we detected SRRM2 expression on plasma cells and normal blood cells to analyze its relationship with clinical profiles. We found widespread positive expression of SRRM2 on plasma cells with little expression on normal blood cells, and its expression on abnormal plasma cells was higher than that on normal plasma cells. Comparative analysis with clinical data suggests that SRRM2 expression on plasma cells correlates with MM treatment response. MM patients with high SRRM2 expression had higher levels of serum \u03b22-mg and LDH, ISS staging, and plasma cell infiltration, as well as high-risk mSMART 3.0 stratification and cytogenetic abnormalities, particularly 1q21 amplification. In patients with previous MM, high SRRM2 expression on plasma cells was associated with higher plasma cell infiltration, high-risk mSMART 3.0 risk stratification, cytogenetic abnormalities, more relapses, and fewer autologous stem cell transplant treatments. In summary, SRRM2 may serve as a novel biomarker and immunotherapeutic target for MM. Its expression level on plasma cells can help in risk stratification of MM and monitoring of treatment response.<\/jats:p>","DOI":"10.1007\/s10238-023-01272-1","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T16:36:04Z","timestamp":1706632564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["SRRM2 may be a potential biomarker and immunotherapy target for multiple myeloma: a real-world study based on flow cytometry detection"],"prefix":"10.1007","volume":"24","author":[{"given":"Jinjing","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqiu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianshan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimai","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"issue":"11","key":"1272_CR1","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, et al. The International consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229\u201353.","journal-title":"Blood"},{"issue":"1","key":"1272_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00428-022-03431-3","volume":"482","author":"F Fend","year":"2023","unstructured":"Fend F, Dogan A, Cook JR. Plasma cell neoplasms and related entities-evolution in diagnosis and classification. Virchows Arch. 2023;482(1):163\u201377.","journal-title":"Virchows Arch"},{"key":"1272_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.exphem.2023.01.002","volume":"119\u2013120","author":"O C\u00e9dile","year":"2023","unstructured":"C\u00e9dile O, Hansen MH, Dahlmann SK, Kristensen TK, Abildgaard N, Nyvold CG. Reproducibility of low-level residual myeloma immunoglobulin detection using ultra-deep sequencing. Exp Hematol. 2023;119\u2013120:14\u201320.","journal-title":"Exp Hematol."},{"issue":"1","key":"1272_CR4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","volume":"21","author":"J Lu","year":"2022","unstructured":"Lu J, Jiang G. The journey of CAR-T therapy in hematological malignancies. Mol Cancer. 2022;21(1):194.","journal-title":"Mol Cancer"},{"key":"1272_CR5","doi-asserted-by":"publisher","first-page":"1027385","DOI":"10.3389\/fimmu.2022.1027385","volume":"13","author":"LS Boussi","year":"2022","unstructured":"Boussi LS, Avigan ZM, Rosenblatt J. Immunotherapy for the treatment of multiple myeloma. Front Immunol. 2022;13:1027385.","journal-title":"Front Immunol"},{"issue":"19","key":"1272_CR6","doi-asserted-by":"publisher","first-page":"11526","DOI":"10.3390\/ijms231911526","volume":"23","author":"A Nogami","year":"2022","unstructured":"Nogami A, Sasaki K. Therapeutic advances in immunotherapies for hematological malignancies. Int J Mol Sci. 2022;23(19):11526.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"1272_CR7","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1182\/blood.2022015481","volume":"139","author":"WJ Chng","year":"2022","unstructured":"Chng WJ. New immunotherapeutic target in myeloma. Blood. 2022;139(16):2417\u20138.","journal-title":"Blood"},{"issue":"15","key":"1272_CR8","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Edavettal S, Mendon\u00e7a M, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020;135(15):1232\u201343.","journal-title":"Blood"},{"key":"1272_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cca.2019.12.026","volume":"503","author":"N Gupta","year":"2020","unstructured":"Gupta N, Sharma A, Sharma A. Emerging biomarkers in multiple myeloma: a review. Clin Chim Acta. 2020;503:45\u201353.","journal-title":"Clin Chim Acta"},{"key":"1272_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1146\/annurev-biochem-013118-111024","volume":"89","author":"R Wan","year":"2020","unstructured":"Wan R, Bai R, Zhan X, Shi Y. How is precursor messenger RNA spliced by the spliceosome? Annu Rev Biochem. 2020;89:333\u201358.","journal-title":"Annu Rev Biochem"},{"key":"1272_CR11","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.60579","volume":"9","author":"\u0130A Ilik","year":"2020","unstructured":"Ilik \u0130A, Malszycki M, L\u00fcbke AK, Schade C, Meierhofer D, Akta\u015f T. SON and SRRM2 are essential for nuclear speckle formation. Elife. 2020;9: e60579.","journal-title":"Elife"},{"issue":"15","key":"1272_CR12","doi-asserted-by":"publisher","first-page":"8599","DOI":"10.1093\/nar\/gkac669","volume":"50","author":"S Xu","year":"2022","unstructured":"Xu S, Lai SK, Sim DY, Ang WSL, Li HY, Roca X. SRRM2 organizes splicing condensates to regulate alternative splicing. Nucleic Acids Res. 2022;50(15):8599\u2013614.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"1272_CR13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749\u201357.","journal-title":"Br J Haematol"},{"issue":"12","key":"1272_CR14","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1272_CR15","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842\u201354.","journal-title":"Cancer"},{"issue":"15","key":"1272_CR16","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1272_CR17","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1272_CR18","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107.","journal-title":"Am J Hematol"},{"issue":"2","key":"1272_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009104","volume":"5","author":"LA Shehadeh","year":"2010","unstructured":"Shehadeh LA, Yu K, Wang L, et al. SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson\u2019s disease. PLoS ONE. 2010;5(2): e9104.","journal-title":"PLoS ONE"},{"issue":"5","key":"1272_CR20","doi-asserted-by":"publisher","first-page":"10566","DOI":"10.1038\/srep10566","volume":"2","author":"J Tomsic","year":"2015","unstructured":"Tomsic J, He H, Akagi K, et al. A germline mutation in SRRM2, a splicing factor gene, is implicated in papillary thyroid carcinoma predisposition. Sci Rep. 2015;2(5):10566.","journal-title":"Sci Rep"},{"issue":"8","key":"1272_CR21","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.gim.2022.04.011","volume":"24","author":"S Cuinat","year":"2022","unstructured":"Cuinat S, Nizon M, Isidor B, et al. Loss-of-function variants in SRRM2 cause a neurodevelopmental disorder. Genet Med. 2022;24(8):1774\u201380.","journal-title":"Genet Med"},{"issue":"1","key":"1272_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40478-021-01219-1","volume":"9","author":"PJ McMillan","year":"2021","unstructured":"McMillan PJ, Strovas TJ, Baum M, et al. Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer\u2019s disease. Acta Neuropathol Commun. 2021;9(1):117.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"1272_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ccell.2017.05.011","volume":"32","author":"M Marchesini","year":"2017","unstructured":"Marchesini M, Ogoti Y, Fiorini E, et al. ILF2 Is a Regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell. 2017;32(1):88-100.e6.","journal-title":"Cancer Cell"},{"issue":"6","key":"1272_CR24","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/cells10061360","volume":"10","author":"J Burroughs Garc\u00eca","year":"2021","unstructured":"Burroughs Garc\u00eca J, Eufemiese RA, Storti P, et al. Role of 1q21 in multiple myeloma: from pathogenesis to possible therapeutic targets. Cells. 2021;10(6):1360.","journal-title":"Cells"},{"issue":"10","key":"1272_CR25","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3389\/fonc.2020.01617","volume":"2","author":"Y Pang","year":"2020","unstructured":"Pang Y, Shao H, Yang Z, et al. The (neutrophils + monocyte)\/lymphocyte ratio is an independent prognostic factor for progression-free survival in newly diagnosed multiple myeloma patients treated With BCD regimen. Front Oncol. 2020;2(10):1617.","journal-title":"Front Oncol"},{"issue":"4","key":"1272_CR26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jgo.2021.12.004","volume":"13","author":"S Giri","year":"2022","unstructured":"Giri S, Dahal S, Bal S, et al. Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myeloma. J Geriatr Oncol. 2022;13(4):486\u201392.","journal-title":"J Geriatr Oncol"},{"issue":"12","key":"1272_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663748","volume":"5","author":"L Zhaoyun","year":"2021","unstructured":"Zhaoyun L, Rong F. Predictive role of immune profiling for survival of multiple myeloma patients. Front Immunol. 2021;5(12): 663748.","journal-title":"Front Immunol"},{"issue":"6","key":"1272_CR28","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3324\/haematol.2012.074872","volume":"98","author":"A Campanella","year":"2013","unstructured":"Campanella A, Santambrogio P, Fontana F, et al. Iron increases the susceptibility of multiple myeloma cells to bortezomib. Haematologica. 2013;98(6):971\u20139.","journal-title":"Haematologica"},{"issue":"9","key":"1272_CR29","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41419-019-1854-0","volume":"10","author":"Y Kong","year":"2019","unstructured":"Kong Y, Hu L, Lu K, et al. Ferroportin downregulation promotes cell proliferation by modulating the Nrf2-miR-17-5p axis in multiple myeloma. Cell Death Dis. 2019;10(9):624.","journal-title":"Cell Death Dis"}],"updated-by":[{"DOI":"10.1007\/s10238-024-01393-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000}}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01272-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01272-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01272-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:08:31Z","timestamp":1732986511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01272-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1272"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01272-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10238-024-01393-1","asserted-by":"object"}]},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]},"assertion":[{"value":"11 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10238-024-01393-1","URL":"https:\/\/doi.org\/10.1007\/s10238-024-01393-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Medical Research Ethics Committee of the Second Affiliated Hospital of Anhui Medical University. Approval No: YJ-YX2021-139.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have approved the manuscript for submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"28"}}